Guardant Health Inc (GH) - News Archive

Guardant Health Showcases Innovative Liquid Biopsy Research at SABCS Amid Strong Revenue Growth Guardant Health, Inc. (NASDAQ: GH), a prominent player in the precision oncology landscape, is set to present 14 abstracts...

PALO ALTO, Calif. In a landmark development for precision oncology, Guardant Health, Inc. (Nasdaq: GH) has announced groundbreaking findings related to its Shield blood test for colorectal cancer (CRC) screening. A rece...

Guardant Health s Strategic Move: A $250 Million Public Offering to Fuel GrowthIn a significant move, Guardant Health, Inc., a trailblazer in precision oncology, has announced the commencement of an underwritten public...

In a significant breakthrough in the fight against early-stage breast cancer, Guardant Health, Inc. has announced promising results from its recent LIBERATE study, published in the esteemed journal ESMO Open. The study...

In a landmark achievement for the field of oncology, Guardant Health, Inc. (Nasdaq: GH), a trailblazer in precision oncology, has sparked significant progress in the detection and treatment of colon cancer through vario...

In the race against cancer, Guardant Health, Inc. (Nasdaq: GH) is setting the pace with groundbreaking developments in multi-cancer detection technologies. At the recent 2025 American Association for Cancer Research (AA...

In a significant move to enhance cancer screening rates and advance precision oncology research, Guardant Health, a recognized leader in precision oncology, has announced partnerships with several organizations aimed at...

The Intersection of Data and Precision Oncology In a significant stride towards advancing cancer therapy research and development, Guardant Health has announced groundbreaking collaborations with two leaders in oncology...

Guardant Health, Inc. (Nasdaq: GH), a prominent player in the precision oncology sector, has recently announced that its innovative Shield multi-cancer detection (MCD) test has been selected by the National Cancer Insti...

In an age where precision medicine increasingly takes centre stage in healthcare, the recent collaboration between Guardant Health, Inc. and Boehringer Ingelheim signifies a monumental step forward in the battle against...

In the dynamic world of oncology, where the complexity of cancer demands innovative solutions, the partnership between COTA Inc. and Guardant Health Inc. represents a monumental shift towards a new frontier in precision...

Liquid Biopsy-Guided Treatment Using Guardant360 CDx Demonstrates Double Survival Rates for Patients with Advanced Cancer: Results from SCRUM-Japan GOZILA Study Published in Nature Medicine PALO ALTO, Calif. Guardant He...

In a striking announcement that underscores its leading role in precision oncology, Guardant Health, Inc. (NASDAQ: GH) revealed it will present pivotal data at the upcoming European Society for Medical Oncology (ESMO) C...

Guardant Health Set to Showcase Breakthroughs in Precision Oncology at ESMO 2024 PALO ALTO, Calif. Guardant Health, Inc. (Nasdaq: GH) is poised to make a significant impact at the upcoming European Society for Medical O...

Guardant Health and Policlinico Gemelli Forge Alliance to Pioneer Liquid Biopsy Services in Italy In an era defined by brisk advancements in medical science, it is with notable excitement that we report the recent colla...

In an era where precision oncology is transforming cancer care, the recent findings from Guardant Health offer a beacon of hope for colorectal cancer (CRC) patients and their healthcare providers. The publication of the...

Guardant Health: Pioneering Advances in Colorectal Cancer Screening and Liquid Biopsy Technology In an era where the precision oncology landscape is rapidly evolving, Guardant Health, Inc., headquartered in Palo Alto, C...

Guardant Health: Pioneering Innovations in Colorectal Cancer Screening and Recognized as a Leader in Impactful Technology PALO ALTO, Calif. In a significant advancement for colorectal cancer (CRC) detection, Guardant He...

Guardant Health Introduces Groundbreaking Upgrade to Liquid Biopsy Test, Revolutionizing Cancer Diagnosis and TreatmentIn a groundbreaking announcement, precision oncology company, Guardant Health, has unveiled a major...

Personalized medicine, driven by innovative biomarker technologies, is revolutionizing the healthcare landscape. As we delve into the rapidly evolving field of personalized medicine, it becomes evident that Guardant Hea...